593 related articles for article (PubMed ID: 29036248)
1. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
Bagel J; Nelson E; Keegan BR
J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
[TBL] [Abstract][Full Text] [Related]
2. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
3. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B
Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117
[TBL] [Abstract][Full Text] [Related]
4. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.
Park KK; Wu JJ; Koo J
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):899-906. PubMed ID: 22702846
[TBL] [Abstract][Full Text] [Related]
5. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
7. Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
Khemis A; Fontas E; Moulin S; Montaudié H; Lacour JP; Passeron T
J Invest Dermatol; 2020 Aug; 140(8):1533-1537.e2. PubMed ID: 32004567
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
9. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
Bagel J
J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
[TBL] [Abstract][Full Text] [Related]
12. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
13. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Bagel J; Nelson E; Riley C; Hetzel A
J Drugs Dermatol; 2020 Dec; 19(12):1149-1155. PubMed ID: 33346509
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis.
De Simone C; D'Agostino M; Capizzi R; Capponi A; Venier A; Caldarola G
Eur J Dermatol; 2011; 21(4):568-72. PubMed ID: 21697032
[TBL] [Abstract][Full Text] [Related]
16. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of UV-based therapy for psoriasis.
Almutawa F; Alnomair N; Wang Y; Hamzavi I; Lim HW
Am J Clin Dermatol; 2013 Apr; 14(2):87-109. PubMed ID: 23572293
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
